Daiichi Sankyo Submits a New Drug Application in Japan for CS-8958,
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
CS-8958 is a laninamivir prodrug that is a Long-Acting Neuraminidase Inhibitor.
The drug, developed entirely for the Japanese market by Daiichi Sankyo, will be
in the form of an inhalant that will directly treat the airways of influenza patients.
Clinical studies to date with adults and children suffering from type A or B influenza
viruses have proven CS-8958 to be effective with a single administration.
In non-clinical studies, CS-8958 has also demonstrated that it is efficacious with
the H1N1 and potentially lethal H5N1 (avian influenza) viruses, leading to an
expectation for wide-ranging contributions to influenza treatment in the future.
In November 2009, Daiichi Sankyo began a Phase III clinical study in Japan on
the prophylactic use of CS-8958.
The drug, developed entirely for the Japanese market by Daiichi Sankyo, will be
in the form of an inhalant that will directly treat the airways of influenza patients.
Clinical studies to date with adults and children suffering from type A or B influenza
viruses have proven CS-8958 to be effective with a single administration.
In non-clinical studies, CS-8958 has also demonstrated that it is efficacious with
the H1N1 and potentially lethal H5N1 (avian influenza) viruses, leading to an
expectation for wide-ranging contributions to influenza treatment in the future.
In November 2009, Daiichi Sankyo began a Phase III clinical study in Japan on
the prophylactic use of CS-8958.
